TG Therapeutics, Inc. $TGTX Shares Bought by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,284 shares of the biopharmaceutical company’s stock after purchasing an additional 500 shares during the period. Kingswood Wealth Advisors LLC’s holdings in TG Therapeutics were worth $298,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in TG Therapeutics by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company’s stock worth $898,000 after buying an additional 8,338 shares during the last quarter. New York State Teachers Retirement System raised its position in TG Therapeutics by 175.0% during the 1st quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company’s stock worth $4,746,000 after buying an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new position in TG Therapeutics during the 1st quarter worth approximately $226,000. GAMMA Investing LLC raised its position in TG Therapeutics by 77.7% during the 1st quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 1,986 shares during the last quarter. Finally, Strs Ohio purchased a new position in TG Therapeutics during the 1st quarter worth approximately $785,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director owned 94,061 shares of the company’s stock, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of TG Therapeutics in a research report on Monday. They set a “buy” rating and a $60.00 price target for the company. B. Riley raised their price target on shares of TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 target price for the company in a report on Thursday, July 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of TG Therapeutics in a report on Wednesday. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.00.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $33.76 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The firm has a market cap of $5.36 billion, a price-to-earnings ratio of 91.24 and a beta of 1.97. The company has a 50 day moving average price of $31.51 and a 200-day moving average price of $35.25. TG Therapeutics, Inc. has a 1-year low of $21.65 and a 1-year high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. During the same period in the prior year, the business posted $0.04 EPS. TG Therapeutics’s revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.